Talking drug development trends with SmartLabs — Fierce Biotech

Nov 13

In this interview with Fierce Biotech I discuss how the biotech industry is shifting from proving that new modalities can be made toward making them at scale and cost-effectively. I walk through how the shift to 20+ therapeutic modalities demands new infrastructure, operations and design thinking—and how SmartLabs’ Universal Lab Framework is built precisely to meet those needs.